Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmentin ES in pediatric CAP and ABRS
NCT05340257Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amoxicillin + clavulanic acid in community acquired pneumonia (CAP), Acute bacterial rhinosinusitis (ABRS), sponsored by GSK. Planned start Oct 2023; status: withdrawn.
02
Drugs
amoxicillin + clavulanic acid
03
Conditions
community acquired pneumonia (CAP)Acute bacterial rhinosinusitis (ABRS)
Beyond the preview
Go deeper on NCT05340257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340257.